Metraipolis › archive › dc_588df20f7653
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial — Europe PMC PMID:40886054
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40886054
- DOI
- 10.1093/ndt/gfaf160
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T01:43:33.006Z
- SHA-256 of the archived text
2fe233b70837748164d41b67a4314b962492c965897f7b01df13527672cb81a9- Stable URL of this page
https://metraipolis.com/documento/dc_588df20f7653
How to cite
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial — Europe PMC PMID:40886054 — Europe PMC (en), https://europepmc.org/article/MED/40886054 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_588df20f7653 (Metraipolis archive dc_588df20f7653, sha256 2fe233b70837748164d41b67a4314b962492c965897f7b01df13527672cb81a9)
BibTeX
@misc{dc588df20f7653,
title = {Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial — Europe PMC PMID:40886054},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40886054},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_588df20f7653; sha256 2fe233b70837748164d41b67a4314b962492c965897f7b01df13527672cb81a9},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40886054. Agents can read the archived copy with the MCP tool read_document.